Copyright Reports & Markets. All rights reserved.

Global Antisense Oligonucleotides Drugs for ATTR Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Inotersen
    • 1.3.3 Eplontersen
    • 1.3.4 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Other
  • 1.5 Global Antisense Oligonucleotides Drugs for ATTR Market Size & Forecast
    • 1.5.1 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity (2021-2032)
    • 1.5.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Akcea Therapeutics
    • 2.1.1 Akcea Therapeutics Details
    • 2.1.2 Akcea Therapeutics Major Business
    • 2.1.3 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product and Services
    • 2.1.4 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Akcea Therapeutics Recent Developments/Updates
  • 2.2 AstraZeneca
    • 2.2.1 AstraZeneca Details
    • 2.2.2 AstraZeneca Major Business
    • 2.2.3 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product and Services
    • 2.2.4 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 AstraZeneca Recent Developments/Updates
  • 2.3 Ionis Pharmaceuticals
    • 2.3.1 Ionis Pharmaceuticals Details
    • 2.3.2 Ionis Pharmaceuticals Major Business
    • 2.3.3 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product and Services
    • 2.3.4 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Ionis Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Antisense Oligonucleotides Drugs for ATTR by Manufacturer

  • 3.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue by Manufacturer (2021-2026)
  • 3.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Antisense Oligonucleotides Drugs for ATTR by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Antisense Oligonucleotides Drugs for ATTR Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Antisense Oligonucleotides Drugs for ATTR Manufacturer Market Share in 2025
  • 3.5 Antisense Oligonucleotides Drugs for ATTR Market: Overall Company Footprint Analysis
    • 3.5.1 Antisense Oligonucleotides Drugs for ATTR Market: Region Footprint
    • 3.5.2 Antisense Oligonucleotides Drugs for ATTR Market: Company Product Type Footprint
    • 3.5.3 Antisense Oligonucleotides Drugs for ATTR Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Antisense Oligonucleotides Drugs for ATTR Market Size by Region
    • 4.1.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2021-2032)
    • 4.1.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Region (2021-2032)
  • 4.2 North America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2021-2032)
  • 4.3 Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value (2021-2032)
  • 4.5 South America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2021-2032)
  • 5.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type (2021-2032)
  • 5.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2021-2032)
  • 6.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application (2021-2032)
  • 6.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2021-2032)
  • 7.2 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2021-2032)
  • 7.3 North America Antisense Oligonucleotides Drugs for ATTR Market Size by Country
    • 7.3.1 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2021-2032)
  • 8.2 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2021-2032)
  • 8.3 Europe Antisense Oligonucleotides Drugs for ATTR Market Size by Country
    • 8.3.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Market Size by Region
    • 9.3.1 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2021-2032)
  • 10.2 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2021-2032)
  • 10.3 South America Antisense Oligonucleotides Drugs for ATTR Market Size by Country
    • 10.3.1 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Market Size by Country
    • 11.3.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Antisense Oligonucleotides Drugs for ATTR Market Drivers
  • 12.2 Antisense Oligonucleotides Drugs for ATTR Market Restraints
  • 12.3 Antisense Oligonucleotides Drugs for ATTR Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Antisense Oligonucleotides Drugs for ATTR and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Antisense Oligonucleotides Drugs for ATTR
  • 13.3 Antisense Oligonucleotides Drugs for ATTR Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Antisense Oligonucleotides Drugs for ATTR Typical Distributors
  • 14.3 Antisense Oligonucleotides Drugs for ATTR Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Antisense Oligonucleotides Drugs for ATTR market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.
    This report is a detailed and comprehensive analysis for global Antisense Oligonucleotides Drugs for ATTR market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antisense Oligonucleotides Drugs for ATTR market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Antisense Oligonucleotides Drugs for ATTR
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Antisense Oligonucleotides Drugs for ATTR market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Akcea Therapeutics, AstraZeneca, Ionis Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Antisense Oligonucleotides Drugs for ATTR market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Inotersen
    Eplontersen
    Other
    Market segment by Application
    Hospital and Clinic
    Retail Pharmacies
    Other
    Major players covered
    Akcea Therapeutics
    AstraZeneca
    Ionis Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Antisense Oligonucleotides Drugs for ATTR product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Antisense Oligonucleotides Drugs for ATTR, with price, sales quantity, revenue, and global market share of Antisense Oligonucleotides Drugs for ATTR from 2021 to 2026.
    Chapter 3, the Antisense Oligonucleotides Drugs for ATTR competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Antisense Oligonucleotides Drugs for ATTR breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Antisense Oligonucleotides Drugs for ATTR market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Antisense Oligonucleotides Drugs for ATTR.
    Chapter 14 and 15, to describe Antisense Oligonucleotides Drugs for ATTR sales channel, distributors, customers, research findings and conclusion.

    Buy now